ELEVATE: Health Professional Perspectives on Eating Disorders and GLP1

Participants

You are eligible to participate if you:

Are a health professional practicing in Australia
Have experiences working with people with lived experience of eating disorders who have taken glucagon-like peptide-1 receptor agonists (GLP1 agonists e.g., Oxempic, Weygovy, Mounjaro, Trizepatide etc., past or current) for obesity or weight related conditions

What is Involved

You will be asked to

Complete a brief screening/demographic survey (approx. 10 min)
Attend a Zoom interview (approx. 60-90 minutes)
If you want and can take part in this study, we will ask you to complete a brief screening/demographic survey and then attend a Zoom interview during which the interviewer will ask the experiences and perspectives of health professionals working with people with lived experience of eating disorders who have taken glucagon-like peptide-1 receptor agonists (GLP1 agonists e.g., Ozempic, Wegovy, Mounjaro, Tirzepatide etc) for obesity or weight related conditions? This will include questions about how you have noticed GLP1 agonists impacting on eating disorder symptoms and treatment engagement and outcomes (during and after (where relevant) taking the medication), how you adjust your treatment approaches for those taking GLP1 agonists, and evidence gaps in terms of weight loss medications and eating disorder treatments.

Participants will receive a small reimbursement of a gift care to the value of $35 in recognition of their participation.

Ethics Approval Number

HEC25174

Organisation

School of Psychology and Public Health La Trobe University

Address

La Trobe University, School of Psychology and Public Health La Trobe University, PO Box 821, 133 McKoy Street, Wodonga, VIC 3689

Phone

+61 2 60249743

Elevate.voices@latrobe.edu.au